BHGZD significantly ameliorates infectious mononucleosis via decreasing the levels of CD3+, CD8+, aspartate aminotransferase (AST), lactic dehydrogenase (LDH), creatine (9CK), and isoenzyme (CK-MB) and increasing the levels of CD4+, CD4+/CD8+, and IgA and IgG (Zhang C. et al., 2016). Here, CD4 is linked to infectious mononucleosis.